|
1
|
GBD Chronic Respiratory Disease
Collaborators. Prevalence and attributable health burden of chronic
respiratory diseases, 1990-2017: a systematic analysis for the
Global Burden of Disease Study 2017. Lancet Respir Med. 8:585–596.
2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Obeidat M and Hall IP: Genetics of complex
respiratory diseases: implications for pathophysiology and
pharmacology studies. Br J Pharmacol. 163:96–105. 2011.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Jameson JL and Longo DL: Precision
medicine - personalized, problematic, and promising. N Engl J Med.
372:2229–2234. 2015.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Collins FS and Varmus H: A new initiative
on precision medicine. N Engl J Med. 372:793–795. 2015.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Haendel MA, Chute CG and Robinson PN:
Classification, Ontology, and Precision Medicine. N Engl J Med.
379:1452–1462. 2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Wörheide MA, Krumsiek J, Kastenmüller G
and Arnold M: Multi-omics integration in biomedical research - A
metabolomics-centric review. Anal Chim Acta. 1141:144–162.
2021.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Sharma J, Shum E, Chau V, Paucar D, Cheng
H and Halmos B: The Evolving Role of Biomarkers in Personalized
Lung Cancer Therapy. Respiration. 93:1–14. 2017.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Salzer HJ, Wassilew N, Köhler N, Olaru ID,
Günther G, Herzmann C, Kalsdorf B, Sanchez-Carballo P, Terhalle E,
Rolling T, et al: Personalized Medicine for Chronic Respiratory
Infectious Diseases: Tuberculosis, Nontuberculous Mycobacterial
Pulmonary Diseases, and Chronic Pulmonary Aspergillosis.
Respiration. 92:199–214. 2016.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Heaney LG and McGarvey LP: Personalised
Medicine for Asthma and Chronic Obstructive Pulmonary Disease.
Respiration. 93:153–161. 2017.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Chung KF: Precision medicine in asthma:
linking phenotypes to targeted treatments. Curr Opin Pulm Med.
24:4–10. 2018.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Karampitsakos T, Juan-Guardela BM,
Tzouvelekis A and Herazo-Maya JD: Precision medicine advances in
idiopathic pulmonary fibrosis. EBioMedicine.
95(104766)2023.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Juan-Guardela BM and Herazo-Maya JD:
Immunity, Ciliated Epithelium, and Mortality: Are We Ready to
Identify Idiopathic Pulmonary Fibrosis Endotypes With Prognostic
Significance? Chest. 161:1440–1441. 2022.PubMed/NCBI View Article : Google Scholar
|
|
13
|
De Sadeleer LJ, Verleden SE, Schupp JC,
McDonough JE, Goos T, Yserbyt J, Bargagli E, Rottoli P, Kaminski N,
Prasse A and Wuyts WA: BAL Transcriptomes Characterize Idiopathic
Pulmonary Fibrosis Endotypes With Prognostic Impact. Chest.
161:1576–1588. 2022.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Vassilakis DA, Sourvinos G, Spandidos DA,
Siafakas NM and Bouros D: Frequent genetic alterations at the
microsatellite level in cytologic sputum samples of patients with
idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 162 (3 Pt
1):1115–1119. 2000.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Townsley DM, Dumitriu B, Liu D, Biancotto
A, Weinstein B, Chen C, Hardy N, Mihalek AD, Lingala S, Kim YJ, et
al: Danazol Treatment for Telomere Diseases. N Engl J Med.
374:1922–1931. 2016.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Podolanczuk AJ, Kim JS, Cooper CB, Lasky
JA, Murray S, Oldham JM, Raghu G, Flaherty KR, Spino C, Noth I and
Martinez FJ: PRECISIONS Study Team. Design and rationale for the
prospective treatment efficacy in IPF using genotype for NAC
selection (PRECISIONS) clinical trial. BMC Pulm Med.
22(475)2022.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Antoniou KM, Tsitoura E, Vasarmidi E,
Symvoulakis EK, Aidinis V, Tzilas V, Tzouvelekis A and Bouros D:
Precision medicine in idiopathic pulmonary fibrosis therapy: From
translational research to patient-centered care. Curr Opin
Pharmacol. 57:71–80. 2021.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Thannickal VJ and Antony VB: Is
personalized medicine a realistic goal in idiopathic pulmonary
fibrosis? Expert Rev Respir Med. 12:441–443. 2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Maher TM, Avram C, Bortey E, Hart SP,
Hirani N, Molyneux PL, Porter JC, Smith JA and Sciascia T:
Nalbuphine tablets for cough in patients with idiopathic pulmonary
fibrosis. NEJM Evid. 2(EVIDoa2300083)2023.PubMed/NCBI View Article : Google Scholar
|
